Literature DB >> 23733341

A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation.

Vincenzo Brancaleone1, Thomas Gobbetti, Nicolas Cenac, Pauline le Faouder, Bartomeu Colom, Roderick J Flower, Nathalie Vergnolle, Sussan Nourshargh, Mauro Perretti.   

Abstract

Endogenous protective pathways mitigate the overshooting of inflammation after sterile or infectious injury. Here we report that formyl peptide receptor 2 (Fpr2/3) null mice display a major phenotype with exacerbated vascular inflammation observed postischemia reperfusion (IR) injury of the mesenteric artery, characterized by marked neutrophil adhesion and extravasation as visualized by intravital microscopy. Analysis of endogenous agonists for Fpr2/3 revealed that lipoxin A4 (LXA4) was generated by platelet/neutrophil aggregates during ischemia: this cellular response was attenuated in Fpr2/3(-/-) mice; hence, LXA4 levels were lower after 30 minutes' ischemia, and associated with augmented vascular inflammation in the reperfusion (45-180 minutes) phase. Exogenous delivery of LXA4 attenuated IR-mediated inflammation in Fpr2/3(+/+) but not Fpr2/3(-/-) mice; conversely, an Fpr2/3 antagonist skewed the vascular phenotype of Fpr2/3(+/+) mice to that of Fpr2/3(-/-) animals. Such LXA4-based circuit could be activated by aspirin (30-100 mg/kg), which triggered formation of 15-epi-LXA4 in wild-type mice, yet it was effective in Fpr2/3(-/-) mice. In summary, we propose that during ischemia, neutrophil Fpr2/3 controls platelet/neutrophil aggregates with the rapid generation of circulating LXA4, which in turn modulates downstream vascular inflammatory responses evident during the reperfusion phase.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23733341      PMCID: PMC3724196          DOI: 10.1182/blood-2013-04-496661

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways.

Authors:  Charles N Serhan
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

2.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes.

Authors:  Jan M Schwab; Nan Chiang; Makoto Arita; Charles N Serhan
Journal:  Nature       Date:  2007-06-14       Impact factor: 49.962

3.  Annexin A1 regulates intestinal mucosal injury, inflammation, and repair.

Authors:  Brian A Babbin; Mike G Laukoetter; Porfirio Nava; Stefan Koch; Winston Y Lee; Christopher T Capaldo; Eric Peatman; Eric A Severson; Roderick J Flower; Mauro Perretti; Charles A Parkos; Asma Nusrat
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

4.  Resolvin D series and protectin D1 mitigate acute kidney injury.

Authors:  Jeremy S Duffield; Song Hong; Vishal S Vaidya; Yan Lu; Gabrielle Fredman; Charles N Serhan; Joseph V Bonventre
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

5.  Annexin-1 modulates repair of gastric mucosal injury.

Authors:  Gary R Martin; Mauro Perretti; Roderick J Flower; John L Wallace
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-01-17       Impact factor: 4.052

Review 6.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

7.  12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis.

Authors:  Gerhard Krönke; Julia Katzenbeisser; Stefan Uderhardt; Mario M Zaiss; Carina Scholtysek; Gernot Schabbauer; Alexander Zarbock; Marije I Koenders; Roland Axmann; Jochen Zwerina; Hans W Baenckler; Wim van den Berg; Reinhard E Voll; Hartmut Kühn; Leo A B Joosten; Georg Schett
Journal:  J Immunol       Date:  2009-08-12       Impact factor: 5.422

8.  Effects of low-dose aspirin on acute inflammatory responses in humans.

Authors:  Thea Morris; Melanie Stables; Adrian Hobbs; Patricia de Souza; Paul Colville-Nash; Tim Warner; Justine Newson; Geoffrey Bellingan; Derek W Gilroy
Journal:  J Immunol       Date:  2009-07-13       Impact factor: 5.422

9.  Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion.

Authors:  Giovanna Leoni; Hetal B Patel; André L F Sampaio; Felicity N E Gavins; Joanne F Murray; Paolo Grieco; Stephen J Getting; Mauro Perretti
Journal:  FASEB J       Date:  2008-08-29       Impact factor: 5.191

10.  Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation.

Authors:  Mauro Perretti; Roderick J Flower; Neil Dufton; Robert Hannon; Vincenzo Brancaleone; Jesmond Dalli; Hetal B Patel; Mohini Gray; Fulvio D'Acquisto; Julia C Buckingham
Journal:  J Immunol       Date:  2010-01-27       Impact factor: 5.422

View more
  45 in total

Review 1.  Prostanoids and NSAIDs in cardiovascular biology and disease.

Authors:  Babettte B Weksler
Journal:  Curr Atheroscler Rep       Date:  2015-07       Impact factor: 5.113

Review 2.  Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.

Authors:  Nan Chiang; Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-31

3.  Activation of ROS/MAPKs/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated diabetic osteoporosis.

Authors:  Yanan An; Haifeng Zhang; Chao Wang; Fangtai Jiao; Hongyue Xu; Xuefei Wang; Wenjing Luan; Fangxue Ma; Lihui Ni; Xudong Tang; Mingyuan Liu; Weiying Guo; Lu Yu
Journal:  FASEB J       Date:  2019-08-28       Impact factor: 5.191

4.  Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice.

Authors:  Guadalupe Ortiz-Muñoz; Beñat Mallavia; Adriaan Bins; Mark Headley; Matthew F Krummel; Mark R Looney
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

Review 5.  Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases.

Authors:  Elizabeth A Middleton; Andrew S Weyrich; Guy A Zimmerman
Journal:  Physiol Rev       Date:  2016-08-03       Impact factor: 37.312

6.  Formyl-Peptide Receptor 2/3/Lipoxin A4 Receptor Regulates Neutrophil-Platelet Aggregation and Attenuates Cerebral Inflammation: Impact for Therapy in Cardiovascular Disease.

Authors:  Shantel A Vital; Felix Becker; Paul M Holloway; Janice Russell; Mauro Perretti; D Neil Granger; Felicity N E Gavins
Journal:  Circulation       Date:  2016-05-06       Impact factor: 29.690

Review 7.  Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Authors:  Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

8.  Lipoxin A4 inhibits NF-κB activation and cell cycle progression in RAW264.7 cells.

Authors:  Yong-Hong Huang; Hong-Mei Wang; Zhen-Yu Cai; Fang-Yun Xu; Xiao-Yan Zhou
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

9.  Endogenous Specialized Proresolving Mediator Profiles in a Novel Experimental Model of Lymphatic Obstruction and Intestinal Inflammation in African Green Monkeys.

Authors:  Felix Becker; Emily Romero; Jason Goetzmann; Dana L Hasselschwert; Beth Dray; John Vanchiere; Jane Fontenot; J Winny Yun; Paul C Norris; Luke White; Melany Musso; Charles N Serhan; J Steven Alexander; Felicity N E Gavins
Journal:  Am J Pathol       Date:  2019-10       Impact factor: 4.307

10.  Intrathecal administration of Resolvin D1 and E1 decreases hyperalgesia in mice with bone cancer pain: Involvement of endocannabinoid signaling.

Authors:  Iryna A Khasabova; Mikhail Y Golovko; Svetlana A Golovko; Donald A Simone; Sergey G Khasabov
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-07-31       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.